| Page 16 | Kisaco Research
 

James Zhu

Partner
JunHe LLP

James Zhu

Partner
JunHe LLP

James Zhu

Partner
JunHe LLP
 

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann
 

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann

The UPC’s Milan Division has drawn new lines on procedural efficiency- finding both excessive invalidity attacks and late-filed arguments unacceptable. This 15 minute update examines the bioMérieux v Labrador decision and its implications for how defendants and plaintiffs must now calibrate their litigation strategy before the UPC.

Author:

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann

Aloys Hüttermann

Patent Attorney
Michalski Hüttermann
 

Daniel Haders, PhD

Chief Executive Officer & Founder
Model Medicines

Daniel Haders, PhD

Chief Executive Officer & Founder
Model Medicines

Daniel Haders, PhD

Chief Executive Officer & Founder
Model Medicines
 

Kunal Jindal

Co-Founder & Chief Technology Officer
CapyBio

Kunal Jindal

Co-Founder & Chief Technology Officer
CapyBio

Kunal Jindal

Co-Founder & Chief Technology Officer
CapyBio
 

Rafael Carazo Salas

Founder & Chief Executive Officer
CellVoyant

Rafael Carazo Salas

Founder & Chief Executive Officer
CellVoyant

Rafael Carazo Salas

Founder & Chief Executive Officer
CellVoyant
 

Adrian Grzybowski

Chief Scientific Officer
AnuBio

Adrian Grzybowski

Chief Scientific Officer
AnuBio

Adrian Grzybowski

Chief Scientific Officer
AnuBio
 

Andrea Costanzo

ARDMS OBGYN

Andrea Costanzo

ARDMS OBGYN

Andrea Costanzo

ARDMS OBGYN
Innovation Incubator Finalists